Abstract
Poly lactic-co-glycolic acid (PLGA) microparticles have been formulated to allow the sustained release of numerous drugs, including antibodies. It is well-known that antibodies are susceptible to chemical and physical stress; therefore, it is necessary to be loaded on PLGA microparticles under mild conditions. In the present study, we constructed cationic porous PLGA microparticles that could be electrostatically adsorbed with infliximab as a model antibody. Cationic porous PLGA microparticles were prepared using the double emulsion method by adding polyethyleneimine and ammonium bicarbonate. After antibody loading, surface pores closure was achieved by mild heating. The size of the optimized formulation was approximately 5 μm, exhibiting a positive charge. The loaded antibody was gradually released from the formulation over 56 days. Based on a tumor necrosis factor (TNF)–α inhibition assay, the released infliximab maintained its pharmacological activity. Collectively, we successfully loaded antibodies into PLGA microparticles while maintaining activity and demonstrating long-acting properties.
Graphical Abstract
Similar content being viewed by others
References
Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022;7(1):39.
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25.
Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126–36.
Okuyama T, Eto Y, Sakai N, Minami K, Yamamoto T, Sonoda H, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1/2 trial. Mol Ther. 2019;27(2):456–64.
Rocha CV, Goncalves V, da Silva MC, Banobre-Lopez M, Gallo J. PLGA-based composites for various biomedical applications. Int J Mol Sci. 2022;23(4):2034.
Alenezi A, Naito Y, Terukina T, Prananingrum W, Jinno Y, Tagami T, et al. Controlled release of clarithromycin from PLGA microspheres enhances bone regeneration in rabbit calvaria defects. J Biomed Mater Res B Appl Biomater. 2018;106(1):201–8.
Tanetsugu Y, Tagami T, Terukina T, Ogawa T, Ohta M, Ozeki T. Development of a sustainable release system for a ranibizumab biosimilar using poly(lactic-co-glycolic acid) biodegradable polymer-based microparticles as a platform. Biol Pharm Bull. 2017;40(2):145–50.
Naito Y, Terukina T, Galli S, Kozai Y, Vandeweghe S, Tagami T, et al. The effect of simvastatin-loaded polymeric microspheres in a critical size bone defect in the rabbit calvaria. Int J Pharm. 2014;461(1–2):157–62.
Colzani B, Pandolfi L, Hoti A, Iovene PA, Natalello A, Avvakumova S, et al. Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles. Int J Nanomedicine. 2018;13:957–73.
Lee PW, Pokorski JK. Poly(lactic-co-glycolic acid) devices: production and applications for sustained protein delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018;10(5): e1516.
Kim H, Park H, Lee J, Kim TH, Lee ES, Oh KT, et al. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials. 2011;32(6):1685–93.
Zhang G-H, Hou R-X, Zhan D-X, Cong Y, Cheng Y-J, Fu J. Fabrication of hollow porous PLGA microspheres for controlled protein release and promotion of cell compatibility. Chin Chem Lett. 2013;24(8):710–4.
Fang K, Yang F, Zhang Q, Zhang T, Gu N. Fabrication of nonporous and porous cationic PLGA microspheres. Mater Lett. 2014;117:86–9.
Kim Y, Sah H. Protein loading into spongelike PLGA microspheres. Pharmaceutics. 2021;13(2):137.
Tamazawa G, Ito A, Miyai T, Matsuno T, Kitahara K, Sogo Y, et al. Gatifloxacine-loaded PLGA and beta-tricalcium phosphate composite for treating osteomyelitis. Dent Mater J. 2011;30(3):264–73.
Meager A. A cytotoxicity assay for tumour necrosis using a human rhabdomyosarcoma cell line. J Immunol Methods. 1991;144(1):141–3.
Wang B, Friess W. Lipid-coated mannitol core microparticles for sustained release of protein. Eur J Pharm Biopharm. 2018;128:91–7.
Miller AC, Bershteyn A, Tan W, Hammond PT, Cohen RE, Irvine DJ. Block copolymer micelles as nanocontainers for controlled release of proteins from biocompatible oil phases. Biomacromolecules. 2009;10(4):732–41.
Nakai T, Hirakura T, Sakurai Y, Shimoboji T, Ishigai M, Akiyoshi K. Injectable hydrogel for sustained protein release by salt-induced association of hyaluronic acid nanogel. Macromol Biosci. 2012;12(4):475–83.
Hong J, Lee Y, Lee C, Eo S, Kim S, Lee N, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade(R) (infliximab). MAbs. 2017;9(2):364–82.
Terukina T, Naito Y, Tagami T, Morikawa Y, Henmi Y, Prananingrum W, et al. The effect of the release behavior of simvastatin from different PLGA particles on bone regeneration in vitro and in vivo: comparison of simvastatin-loaded PLGA microspheres and nanospheres. J Drug Deliv Sci Technol. 2016;33:136–42.
Ozeki T, Kaneko D, Hashizawa K, Imai Y, Tagami T, Okada H. Improvement of survival in C6 rat glioma model by a sustained drug release from localized PLGA microspheres in a thermoreversible hydrogel. Int J Pharm. 2012;427(2):299–304.
Wang G, Pan L, Zhang Y, Wang Y, Zhang Z, Lu J, et al. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS One. 2011;6(11): e27605.
Elsaid N, Jackson TL, Elsaid Z, Alqathama A, Somavarapu S. PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of Ranibizumab. Mol Pharm. 2016;13(9):2923–40.
Wang C, Yang J, Han H, Chen J, Wang Y, Li Q, et al. Disulfiram-loaded porous PLGA microparticle for inhibiting the proliferation and migration of non-small-cell lung cancer. Int J Nanomedicine. 2017;12:827–37.
Kim I, Byeon HJ, Kim TH, Lee ES, Oh KT, Shin BS, et al. Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials. 2013;34(27):6444–53.
Funding
This work was partly supported by JSPS KAKENHI Grant Number 20K07203 and the Eye Research Foundation for the Aged (EFRA).
Author information
Authors and Affiliations
Contributions
Ayaka Hanaki: conceptualization, methodology, investigation, writing—original draft, visualization. Koki Ogawa: data curation, formal analysis, writing—original draft, supervision. Tatsuaki Tagami: conceptualization, writing—review and editing, supervision. Tetsuya Ozeki: resources, funding, writing—review and editing, supervision.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no conflicts of interest associated with this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hanaki, A., Ogawa, K., Tagami, T. et al. Fabrication and Characterization of Antibody-Loaded Cationic Porous PLGA Microparticles for Sustained Antibody Release. AAPS J 25, 92 (2023). https://doi.org/10.1208/s12248-023-00859-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/s12248-023-00859-6